Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Financial Bull 3X Shares ETF
FAS
US Stock MarketDetailed Quotes
Tenaya Therapeutics (TNYA)
- 0.6603
- -0.0307-4.44%
Close Apr 29 16:00 ET
- 0.6607
- +0.0004+0.06%
Pre 05:20 ET
143.28MMarket Cap-1.12P/E (TTM)
0.7000High0.6550Low3.23MVolume0.7000Open0.6910Prev Close2.17MTurnover1.94%Turnover RatioLossP/E (Static)217.00MShares2.350052wk High1.16P/B110.12MFloat Cap0.360052wk Low--Dividend TTM166.77MShs Float32.0000Historical High--Div Yield TTM6.51%Range %0.3600Historical Low0.6705Avg Price1Lot Size
TNYA Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
TNYA Orderflow
Unit: --
TNYA Orderflow Trend
IntradayDayWeekMonth
No Data
Tenaya Therapeutics (TNYA) News
Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation
Express News | Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data From Ridge™-1 Phase 1B/2 Clinical Trial of Tn-401 Gene Therapy in Adults With Pkp2-Associated Arvc at Asgct 2026
Tenaya Therapeutics Duchenne Muscular Dystrophy Treatment Granted Orphan Status
Tenaya's TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Chardan Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Cuts Target Price to $8
Tenaya Therapeutics (TNYA) Stock Forum
$Tenaya Therapeutics (TNYA.US)$ Late-Breaking Oral Presentation of New Clinical Data From Ridge™-1 Phase 1B/2 Clinical Trial of Tn-401 Gene Therapy in Adults With Pkp2-Associated Arvc at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, taking place May 15, 2026.
*Interim Data from RIDGE-1: A Phase 1b/2 Interventional Study to Evaluate Safety and Efficacy of TN-401, an AAV9 Investigational Gene Replacement Therapy, in Adults with PKP2-Associa...
*Interim Data from RIDGE-1: A Phase 1b/2 Interventional Study to Evaluate Safety and Efficacy of TN-401, an AAV9 Investigational Gene Replacement Therapy, in Adults with PKP2-Associa...
$Tenaya Therapeutics (TNYA.US)$ another bull run coming?
$Tenaya Therapeutics (TNYA.US)$
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
by Globe Newswire
Follow
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
New Data Confirm TN-301's Differentiated Mechanism and Opportunities to Positively Address...
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
by Globe Newswire
Follow
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
New Data Confirm TN-301's Differentiated Mechanism and Opportunities to Positively Address...
2
1
$Tenaya Therapeutics (TNYA.US)$ 🚀🚀🚀🚀🚀 $1
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)